期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

希罗达治疗晚期恶性肿瘤的临床疗效观察 被引量：2

下载PDF
导出
摘要 ①目的探讨希罗达治疗晚期恶性肿瘤的疗效及其毒性反应。②方法21例晚期恶性肿瘤患者采用希罗达治疗14天,停药7天为1治疗周期,共治疗至少2周期以上。③结果21例中1例CR,7例PR,8例SD,5例PD;有效率(CR+PR)为38.1%,肿瘤控制率为(CR+PR+SD)为76.2%。不良反应轻微,多为Ⅰ/Ⅱ级。④结论希罗达治疗老年或体质差的晚期恶性肿瘤,疗效较好,毒副反应轻。
作者 惠双 万里新 孙晓 屈中玉 魏光敏
机构地区 河南省南阳市中心医院
出处 《华北煤炭医学院学报》 2005年第3期322-323,共2页 Journal of North China Coal Medical College
关键词 恶性肿瘤 晚期 希罗迭 化疗/药物治疗
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1孙燕.临床肿瘤内科手册[M].第4版.北京:人民卫生出版社,2001.591-592
  • 2Miwa M,Nishidaum,Ishikawa ST,et al.Disign of a novel oral fluoropy rimidine carbamate capelitabine which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and Cancer[J].Eur J Carcer,1998,34(8):1274
  • 3Schueller J,Cassidy,Dumont E,et al.preferential ac ivation of Capecitabine in tumor following oral adminstration to colorectal patients[J].Cancer Chemother Pharmacol,2000,45(2):291
  • 4储大同,刘基巍,李维廉,宋三泰,赵扬冰,宋恕平,赵龙妹,朱建新,王怀谨,张嘉庆,北京希罗达治疗乳腺癌协作组100021.希罗达治疗转移性乳腺癌的疗效和安全性的临床研究[J].临床肿瘤学杂志,2003,8(5):321-324. 被引量：16
  • 5郑涛,陈伟,王树滨,白桦,郑瑾,夏俊贤,叶建增,田忠凯.希罗达治疗晚期乳腺癌疗效观察[J].中国肿瘤临床与康复,2004,11(1):61-63. 被引量：3
  • 6管忠震,刘冬耕,郁宝铭,吴唯勤,时德,赵瑜,魏于全,邹立群,伍晓汀,庄文,冯奉仪,张频,于世英,熊慧华,付强,郑树,黄建瑾,伍钢,杨传永,孙圣荣,阮庆兰.希罗达一线治疗晚期或复发性结直肠癌[J].中华肿瘤杂志,2004,26(2):119-121. 被引量：72

二级参考文献24

  • 1Seidman AD, O'Shaughnessy J, Misaet J. Single-agent Capecitabine: a reference treatment for Taxane-pretreated metastatic breast cancer[J]. Oncolagist, 2002, 7(auppl 6) :20 -28.
  • 2Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer[J]. Oncologist, 2001,6( 1 ) :56 -64.
  • 3Schueller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal patients[ J]. Cancer Chemother Pharmacol, 45:291 - 297,2000.
  • 4Blum JL, dieras V, Lo Russo PM, et al. Multicenter, phase Ⅱ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients[ J]. Cancer, 2001,92 : 1759 - 1768.
  • 5Fumoleau P, Laigillier R, Trillet-Lenoir V, et al. Phase Ⅱ study of capecitabine ( Xeloda ) in pts with advanced breast cancer ( ABC ), previously treated with anthracyclines and taxanes[ J]. Breast Cancer Res Treat,2001, 69:285a.
  • 6Reichardt P, Von Minckwitz G, Luck HJ, et al. Capecitabine:the new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large muhicenter phase Ⅱ trial[J]. Eur J Cancer, 2001, 37 ( suppl6) :S191a.
  • 7Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine (capecitabine)[ J]. Biol Pharm Bull, 1998, 21 :713-717.
  • 8Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of S-Fum by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [ J ]. Biochem Pharmacol,1998, 55 : 1091 - 1097.
  • 9Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts [ J ]. Cancer Res,1998, 58:685 -690.
  • 10Venturini M. Rational development of capecitabine [ J ]. Eur J Cancer, 2002, 38:S3-S9.

共引文献81

同被引文献9

引证文献2

二级引证文献3

华北煤炭医学院学报
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部